Ureteroscope Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035

The Ureteroscope Market exceeded USD 1.56 billion in 2025 and is projected to grow at 8.3% CAGR to reach USD 3.45 billion by 2035.

The burden of stone disease supports continuing demand for endourology procedures, while better diagnostic access brings previously underdetected cases into treatment pathways. This connects procurement with a recurring clinical need rather than a single equipment cycle. Growth in ambulatory surgery changes the preferred ownership and workflow model. Facilities focused on predictable scheduling and lean support can use disposable scopes to avoid maintaining local reprocessing operations. Digital single-use products also narrow the performance gap with premium reusable systems through improved imaging, active deflection, and integrated visualization. Customers can therefore evaluate disposables in a wider set of procedures without accepting the same repair exposure or turnaround requirements. These developments broaden procurement choices while making clinical performance and operational suitability central to decisions across hospital and outpatient settings.

Based on product type, flexible ureteroscopes generated USD 1.06 billion in global revenue in 2025. Maneuverability and compatibility with laser lithotripsy support procedures requiring access within the kidney's collecting system. Digital imaging improves visualization and helps address complex stone-management requirements. Reusable and single-use products compete within these applications while offering different ownership and support arrangements. Suppliers need to align performance with the provider's workflow and intended procedures. The segment's commercial relevance therefore combines a clinical requirement for access and visualization with practical choices about device management. Manufacturers able to provide suitable imaging and handling characteristics can address customers assessing both procedural capability and the operating implications of the platform they select.

By usability, reusable ureteroscopes are projected to reach USD 1.62 billion by 2035. Hospital capital budgets, established sterile-processing departments, and high procedural volumes support continued purchasing. Facilities with mature reprocessing operations can manage turnaround and repair exposure within their existing systems. This preserves a practical role for premium reusable digital devices even as disposable options expand. Suppliers serving the segment need dependable instruments and service suited to those workflows. The category's commercial position therefore reflects operational fit rather than a uniform preference for one technology model. Customers evaluate durability, available processing capability, and procedure needs together, making the relationship between device performance and the provider's existing infrastructure important to procurement decisions.

The North America ureteroscope market generated USD 593 million in 2025. Substantial procedure volumes, advanced endourology services, and established ambulatory surgery networks support digital and single-use products. Historical reimbursement arrangements also contributed to the development of disposable urinary tract endoscopy. Suppliers compete within a mature procurement environment where service responsiveness and contract access matter alongside clinical capabilities. Customers need platforms suitable for their procedure setting and operational resources. The regional market therefore combines established hospital demand with outpatient adoption, creating different opportunities for reusable and disposable offerings. Manufacturers able to support both performance requirements and practical purchasing arrangements can address providers whose device choices increasingly reflect the complete workflow of stone-management services.

Boston Scientific Corporation accounted for 25% of market share in 2025. LithoVue supports its position in single-use flexible ureteroscopy, while StoneSmart Solutions connects visualization with lithotripsy, irrigation, and accessories. This broader approach addresses customers evaluating the complete procedural workflow rather than a scope alone. Hospitals and ambulatory facilities need products that work together within their service model, making integration commercially useful. Boston Scientific's position therefore reflects both the device franchise and a wider stone-management portfolio. Connecting several functions can strengthen account relationships where buyers seek consistent access to procedural tools, while the single-use offering addresses customers evaluating sterile availability and the operating demands associated with reusable equipment.

Some of the major players in this market are Olympus Corporation, Karl Storz SE and Co. KG, Ambu A/S, OPCOM Medical, Coloplast, Dornier MedTech, and Richard Wolf. Olympus combines reusable relationships with a growing disposable portfolio. Karl Storz emphasizes durable instruments and hospital integration, while Ambu focuses on sterile single-use availability in leaner settings. OPCOM addresses customers seeking disposable benefits at competitive acquisition prices. Other companies participate through wider urology ranges and focused endoscopy development. Competition increasingly involves imaging, service economics, device dimensions, and integrated procedures. Suppliers must connect those features with clinician preferences and procurement requirements, making dependable support and the ability to serve different device models important across hospitals and outpatient facilities.